My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Budesonide
    Budesonide

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1704
    CAS #: 51333-22-3Purity ≥98%

    Description: Budesonide is a potent glucocorticoid steroid used for the treatment of asthma, non-infectious rhinitis, and for treatment and prevention of nasal polyposis. Additionally, it is used for Crohn's disease (inflammatory bowel disease). Budesonide has shown the potent glucocorticoid activity and little mineralocorticoid activity. In addition, Budesonide has been reported to have a wide range of inhibitory activities against multiple cells types and mediators involved in allergic and nonallergic-mediated inflammatory. 

    References: J Immunol. 1999 Nov 15;163(10):5624-32; Vascul Pharmacol. 2005 Aug;43(2):101-11.

    Related CAS: 51372-29-3  [(22R)-Budesonide]

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)430.53
    FormulaC25H34O6
    CAS No.51333-22-3
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 86 mg/mL (199.7 mM)
    Water:<1 mg/mL
    Ethanol: 19 mg/mL (44.1 mM)
    Other info

    Chemical Name: (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5] indeno[1,2-d][1,3]dioxol-4(2H)-one

    InChi Key: VOVIALXJUBGFJZ-KWVAZRHASA-N

    InChi Code: InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1

    SMILES Code: O=C(C=C[[email protected]@]12C)C=C1CC[[email protected]@]([[email protected]]2([H])[[email protected]@H](O)C[[email protected]@]34C)([H])[[email protected]]3([H])C[[email protected]]5([H])[[email protected]@]4(C(CO)=O)OC(CCC)O5

    Synonyms

    Rhinocort Rhinosol Pulmicort Budicort Entocort Symbicort Noex Entocort EC


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Budesonide effectively inhibits production of eotaxin and RANTES protein although Budesonide inhibits the expression of chemokine mRNA to a variable extent in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide inhibits both RANTES- and eotaxin promoter-driven reporter gene activity in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide also selectively accelerates the decay of eotaxin and MCP-4 mRNA in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide time- and protein synthesis-dependently reduces VEGF secretion and VEGF mRNA expression in both cell types and these effects are inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that Budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. Budesonide causes a dose-dependent, almost total, inhibition of swine dust-induced IL-6 and IL-8 release from epithelial cells and LPS-induced IL-6 and TNF-alpha from alveolar macrophages.

    In VivoBudesonide totally prevents the increased production of TNF-alpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low (2.5 mg/mL/kg) and high (50 mg/mL/kg) concentrations in rats. Budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9 in A/J mice. 
    Animal modelMice
    Formulation & Dosage2.5, 50 mg/mL/kg
    References

    J Immunol. 1999 Nov 15;163(10):5624-32; Vascul Pharmacol. 2005 Aug;43(2):101-11.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?